Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Kidney Cancer

This study has suspended participant recruitment.
(Enrollment will resume once new arm (bladder) is approved and activated.)
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
GlaxoSmithKline
Novartis
Information provided by (Responsible Party):
Toni Choueiri, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01184326
First received: August 17, 2010
Last updated: January 14, 2014
Last verified: January 2014

August 17, 2010
January 14, 2014
September 2010
December 2014   (final data collection date for primary outcome measure)
  • Maximum tolerated dose [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    To determine the maximum tolerated dose and dose limiting toxicities of the combination of pazopanib and everolimus
  • Expansion Cohort: Safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    To determine the safety of pazopanib and everolimus in patients with metastatic kidney cancer who have had previous treatment with VEGF receptor inhibition.
Same as current
Complete list of historical versions of study NCT01184326 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the pharmacokinetics of the combination of pazopanib and everolimus.
  • Expansion Cohort: Response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the objective resonse proportion, progression-free survival, and duration of response.
Same as current
Not Provided
Not Provided
 
Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Kidney Cancer
A Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Kidney Cancer

This research study is evaluating the combination of pazopanib and everolimus in patients that have a malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or metastatic or locally advanced unresectable kidney cancer. In this research study the investigators are testing the safety of the combination of pazopanib and everolimus as well as to find the appropriate dose to use for further studies.

  • This protocol has two parts, Phase I and Expansion Cohort. Once the maximum tolerated dose has been identified in the Phase I portion, an expansion cohort of patients with metastatic or locally advanced unresectable kidney cancer will be enrolled.
  • Each treatment cycle lasts 4 weeks during which the participant will be taking pazopanib and everolimus orally daily.
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Solid Tumor
  • Kidney Cancer
  • Drug: pazopanib
    Taken orally once daily
  • Drug: everolimus
    Taken orally once daily
    Other Name: RAD001
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
44
June 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Phase I: Participants must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effected.
  • Expansion Cohort Only: Participants must have histologically or cytologically confirmed metastatic or locally advanced unresectable kidney cancer.
  • Expansion Cohort Only: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension at 20mm or greater with conventional techniques or as 10mm or greater with spiral CT.
  • Expansion Cohort Only: Previously treated with at least one anti-angiogenic agent, including but not limited to bevacizumab, sunitinib, or sorafenib. No more than 4 lines of prior systemic therapy for kidney cancer, mTOR pathway inhibitors other than RAD001 are allowed.
  • 18 years of age or older
  • Life expectancy of greater than 3 months
  • ECOG performance status of 0 or 1
  • Normal organ and marrow function as outlined in the protocol
  • Able to swallow oral medications
  • Resolution of any pre-existing toxicity from prior therapy to NCI CTCAE v4.0 grade 1 or less
  • Women are eligible to participate if she is of non-child bearing potential or agrees to use adequate contraception
  • Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
  • A male with a female partner of childbearing potential must use a barrier method of contraception or abstinence during the study

Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or thos who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Current treatment with leuprolide or other GnRH agonists is permitted on the Phase 1 portion of the study.
  • Participants may not be receiving any other study agents.
  • Prior RAD001 or pazopanib therapy
  • History of clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 weeks prior to the first dose of study drug.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or everolimus
  • History of any of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting; myocardial infarction; unstable angina; coronary artery by-pass graft surgery; symptomatic peripheral vascular disease; Class III or IV congestive heart failure
  • Poorly controlled hypertension
  • History of cerebrovascular accident, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months
  • Prior major surgery or trauma within 28 days prior to first dose of study drug, and/or not recovered from effects of that surgery, and/or presences of an non-healing wound, fracture or ulcer, or patients that may require surgery during the course of treatment
  • Evidence of active bleeding or bleeding diathesis
  • Known endobronchial lesions or involvement of large pulmonary vessels by tumor
  • Hemoptysis within 6 weeks of the first dose of study drug
  • Clinically significant gastrointestinal abnormalities that may increase the risk of GI bleeding
  • Expansion Cohort Only: Currently active second malignancy other than non-melanoma skin cancers
  • Presence of uncontrolled infection
  • Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitis
  • Uncontrolled diabetes
  • Pregnant or breastfeeding
  • Chronic treatment with systemic corticosteroids or other immunosuppressive agent
  • Treatment with strong CYP3A4 inhibitors
  • Treatment with strong CYP3A4 inducers
  • Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
  • Prolongation of corrected QT interval > 480msecs
  • History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
  • Any ongoing toxicity from prior anti-cancer therapy that is greater than grade 1 and/or that is progressing in severity.
  • Any serious and/or pre-existing medical, psychiatric, or other condition that could interfere with subject safety, obtaining informed consent or compliance with study procedures
  • HIV-positive individuals on combination antiretroviral therapy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01184326
10-166
Yes
Toni Choueiri, MD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • GlaxoSmithKline
  • Novartis
Principal Investigator: Jonathan Rosenberg, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP